AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune, a privately-held, Maryland, US-based biologics company focused on developing novel therapeutics in cancer immunology.
{iframe}http://www.astrazeneca.com/Media/Press-releases/Article/20130826-medimmune-strengthens-immunemediated-cancer-therapy{/iframe}